Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (Q53428610)
Jump to navigation
Jump to search
scientific article published on 13 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. |
scientific article published on 13 July 2015 |
Statements
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer (English)
Lecia V Sequist
Giorgio Scagliotti
Joachim von Pawel
Fabrice Barlesi
Wallace Akerley
David Spigel
Vera Hirsh
Frances A Shepherd
Alan Sandler
Jeffrey S Ross
Qiang Wang
Reinhard von Roemeling
Dale Shuster
13 July 2015